Cargando…

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model

The mechanistic target of rapamycin (mTOR), a serine-threonine kinase, plays a pivotal role in regulating cell growth and proliferation. Notably, a great deal of evidence indicates that mTOR signaling is also crucial in controlling proliferation and differentiation of several stem cell compartments....

Descripción completa

Detalles Bibliográficos
Autores principales:	Polchi, Alice, Magini, Alessandro, Meo, Danila Di, Tancini, Brunella, Emiliani, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983755/ https://www.ncbi.nlm.nih.gov/pubmed/29772672 http://dx.doi.org/10.3390/ijms19051474

Ejemplares similares

Rapamycin Loaded Solid Lipid Nanoparticles as a New Tool to Deliver mTOR Inhibitors: Formulation and in Vitro Characterization
por: Polchi, Alice, et al.
Publicado: (2016)

Curcumin Analogue C1 Promotes Hex and Gal Recruitment to the Plasma Membrane via mTORC1-Independent TFEB Activation
por: Magini, Alessandro, et al.
Publicado: (2019)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Signaling Pathways in Exosomes Biogenesis, Secretion and Fate
por: Urbanelli, Lorena, et al.
Publicado: (2013)

Biocompatible Polymer Nanoparticles for Drug Delivery Applications in Cancer and Neurodegenerative Disorder Therapies
por: Calzoni, Eleonora, et al.
Publicado: (2019)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

Raptor Preys on mTOR Imbalance in Tuberous Sclerosis
por: Ramamurthy, Aishwarya, et al.
Publicado: (2023)

Oncogenic H-Ras Up-Regulates Acid β-Hexosaminidase by a Mechanism Dependent on the Autophagy Regulator TFEB
por: Urbanelli, Lorena, et al.
Publicado: (2014)

YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)

Is mTOR inhibition a systemic treatment for tuberous sclerosis?
por: Moavero, Romina, et al.
Publicado: (2013)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021)

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
por: Major, Philippe
Publicado: (2011)

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2014)

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
por: Palavra, Filipe, et al.
Publicado: (2017)

Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis
por: Zimmer, Till S., et al.
Publicado: (2020)

Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014)

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020)

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
por: Zhang, Bo, et al.
Publicado: (2013)

Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
por: Brakemeier, Susanne, et al.
Publicado: (2017)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review
por: Sugalska, Monika, et al.
Publicado: (2021)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth
por: Dill, Patricia E, et al.
Publicado: (2015)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
por: Franz, David N., et al.
Publicado: (2017)

Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex
por: McNamara, Molly C., et al.
Publicado: (2022)

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
por: Śmiałek, Dominika, et al.
Publicado: (2023)

Cellular antiseizure mechanisms of everolimus in pediatric tuberous sclerosis complex, cortical dysplasia, and non–mTOR‐mediated etiologies
por: Cepeda, Carlos, et al.
Publicado: (2018)

Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility
por: Tomoto, Kyoichi, et al.
Publicado: (2021)

mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile
por: Pawlik, Bartłomiej, et al.
Publicado: (2022)

Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting
por: Kapur, Payal, et al.
Publicado: (2023)

Tuberous sclerosis complex tumor suppressor–mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent
por: Jaeschke, Anja, et al.
Publicado: (2002)

PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex
por: Alves, Maria M., et al.
Publicado: (2015)

The long-term effect of mTOR inhibition on lipid and glucose metabolism in tuberous sclerosis complex: data from the Dutch TSC registry
por: Mulder, Femke V. M., et al.
Publicado: (2022)

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma()
por: Cho, Jinhyun, et al.
Publicado: (2016)

Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study
por: Saffari, Afshin, et al.
Publicado: (2019)

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
por: Pollizzi, Kristen, et al.
Publicado: (2009)

Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia
por: Olney, Nicholas T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gjpba21oumhl9bu58qsa77pf5e